Roche announced results from the positive, pivotal phase III IMpower150 study
Roche announced results from the positive, pivotal Phase III IMpower150 study of Tecentriq® (atezolizumab) and Avastin® (bevacizumab) plus chemotherapy (carboplatin and paclitaxel) in people with previously untreated advanced non-squamous NSCLC. December 07, 2017